AWM Investment Company Inc. Sells 5,000 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• AWM Investment Company Inc. reduced its stake in LeMaitre Vascular, Inc. by 3.3%, owning 145,000 shares valued at approximately $12.17 million after selling 5,000 shares.
• LeMaitre Vascular reported a 15% increase in quarterly revenue year-over-year, with earnings per share surpassing expectations at $0.60, compared to estimates of $0.57.
• The company declared a quarterly dividend of $0.20 per share, which reflects an annualized yield of 0.8%, with a payout ratio of 38.83%.

AWM Investment Company Inc. lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 145,000 shares of the medical instruments supplier's stock after selling 5,000 shares during the period. LeMaitre Vascular makes up 1.7% of AWM Investment Company Inc.'s investment portfolio, making the stock its 24th largest position. AWM Investment Company Inc. owned about 0.64% of LeMaitre Vascular worth $12,166,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $26,000. NBC Securities Inc. purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $36,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $50,000. US Bancorp DE raised its holdings in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 368 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of LeMaitre Vascular by 11.5% during the 4th quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after buying an additional 284 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Down 0.1%

Shares of LMAT traded down $0.08 on Monday, reaching $97.42. The stock had a trading volume of 25,301 shares, compared to its average volume of 189,102. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of 47.21, a price-to-earnings-growth ratio of 2.51 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The company has a 50-day simple moving average of $88.64 and a 200-day simple moving average of $86.10. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The company had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. LeMaitre Vascular's payout ratio is presently 38.83%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director directly owned 17,976 shares of the company's stock, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LMAT shares. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.